دسترسی نامحدود
برای کاربرانی که ثبت نام کرده اند
برای ارتباط با ما می توانید از طریق شماره موبایل زیر از طریق تماس و پیامک با ما در ارتباط باشید
در صورت عدم پاسخ گویی از طریق پیامک با پشتیبان در ارتباط باشید
برای کاربرانی که ثبت نام کرده اند
درصورت عدم همخوانی توضیحات با کتاب
از ساعت 7 صبح تا 10 شب
ویرایش: نویسندگان: Ganji Seeta Rama Raju, L. V. K. S. Bhaskar سری: ISBN (شابک) : 9789811520174 ناشر: Springer Singapore سال نشر: 2020 تعداد صفحات: 0 زبان: English فرمت فایل : EPUB (درصورت درخواست کاربر به PDF، EPUB یا AZW3 تبدیل می شود) حجم فایل: 12 مگابایت
در صورت ایرانی بودن نویسنده امکان دانلود وجود ندارد و مبلغ عودت داده خواهد شد
در صورت تبدیل فایل کتاب Theranostics Approaches to Gastric and Colon Cancer به فرمت های PDF، EPUB، AZW3، MOBI و یا DJVU می توانید به پشتیبان اطلاع دهید تا فایل مورد نظر را تبدیل نمایند.
توجه داشته باشید کتاب رویکردهای Theranostics به سرطان معده و روده بزرگ نسخه زبان اصلی می باشد و کتاب ترجمه شده به فارسی نمی باشد. وبسایت اینترنشنال لایبرری ارائه دهنده کتاب های زبان اصلی می باشد و هیچ گونه کتاب ترجمه شده یا نوشته شده به فارسی را ارائه نمی دهد.
این کتاب بر اهمیت درک متابولیسم سرطان معده و روده بزرگ در هدایت تشخیص و کشف دارو تاکید می کند. این ارتباط بین آدیپونکتین و ماتریکس متالوپروتئیناز را با سرطان کولورکتال خلاصه می کند. این کتاب همچنین نقش واگرای فاکتور 1 القاکننده هیپوکسی را در رشد و متاستاز سرطان کولورکتال ارزیابی می کند. پس از بحث در مورد نقش پلیمورفیسمهای ژنتیکی در آنزیمهای متابولیزه کننده الکل و EPHX1 با شروع سرطان کولورکتال، مکانیسمهای مولکولی مقاومت شیمیایی در سرطان معده و استراتژیهای درمانی جدید برای معکوس کردن مقاومت شیمیایی تومورها بررسی میشود. علاوه بر این، این کتاب به بررسی نقش ترانوستیک نانوذرات و پتانسیل درمانی فیتوکمیکالها با توجه به سرطان کولورکتال میپردازد. با توجه به دامنه آن، این کتاب راهنمای ارزشمندی برای انکولوژیست ها، محققان دانشگاهی، پزشکان داروسازی و دانشجویانی که در تحقیقات و درمان سرطان نقش دارند ارائه می دهد.
This book highlights the importance of understanding gastric and colon cancer metabolism in guiding diagnosis and drug discovery. It summarizes the correlation between adiponectin and matrix metalloproteinase with colorectal cancer. The book also evaluates the divergent role of hypoxia-inducible factor 1 in colorectal cancer growth and metastasis. After discussing the role of genetic polymorphisms in alcohol metabolizing enzymes and EPHX1 with the onset of colorectal cancer, it reviews the molecular mechanisms of chemoresistance in gastric cancer and novel therapeutic strategies to reverse the chemoresistance of tumors. In addition, the book explores the theranostic role of nanoparticles and therapeutic potential of phytochemicals with regard to colorectal cancer. Given its scope, the book offers a valuable guide for oncologists, academic researchers, pharmaceuticals practitioners, and students who are involved in research and treatment of cancer.
Preface Contents About the Series Editor About the Editors Chapter 1: Therapeutic Role of Phytochemicals in Colorectal Cancer 1.1 Introduction 1.2 Classification 1.2.1 Polyphenols 1.2.2 Phenolic Acids 1.2.3 Derivatives of Benzoic Acid 1.2.4 Derivatives of Cinnamic Acid 1.2.5 Flavonoids 1.2.6 Anthocyanins 1.2.7 Flavones and Flavanones 1.2.8 Flavanols 1.3 Isoflavones 1.3.1 Genistein 1.4 Stilbenes 1.5 Pterostilbene 1.5.1 Resveratrol 1.6 Curcuminoid 1.6.1 Curcumin 1.7 Conclusion References Chapter 2: Adiponectin Signaling in Colorectal Cancer 2.1 Introduction 2.2 Biology of Adiponectin and Its Receptors 2.3 Adeponectin Receptors 2.4 Obesity Adiponectin CRC 2.5 Evidence for the Association Between the Adiponectin and CRC 2.6 Adiponectin Mediated Signalling in CRC 2.7 Epidemiological Studies 2.8 In Vitro and In Vivo Experiments 2.9 Therapeutic Role of Adiponectin 2.10 Conclusion References Chapter 3: Role of Matrix Metalloproteinases in Colorectal Cancer 3.1 Introduction 3.2 Role of Matrix Metalloproteinases in Colorectal Cancer 3.2.1 Role of MMP1 in CRC 3.2.2 Role of MMP13 in CRC 3.2.3 Role of MMP2 in CRC 3.2.4 Role of MMP9 in CRC 3.2.5 Co-expression of MMP3 and MMP9 in CRC 3.2.6 Role of MMP7 in CRC 3.2.7 Role of MMP13 in CRC 3.2.8 Role of MT1-MMP in CRC 3.2.9 Role of MMP12 in CRC 3.3 Role of Tissue Inhibitors of Metalloproteinases in Colorectal Cancer 3.4 MMPs as Therapeutic Target References Chapter 4: The Role of Hypoxia-Inducible Factor 1-Alpha in Colorectal Cancer 4.1 Introduction 4.1.1 Overview of Colorectal Cancer 4.1.2 Basic Pathophysiology of Colorectal Cancer 4.1.3 HIF-1-Alpha 4.2 Role of HIF-1-Alpha in Colorectal Cancer 4.3 Current Investigations 4.4 Conclusion References Chapter 5: Mechanisms and Pathways of Metabolic Reprogramming of Colorectal Cancer 5.1 Highlights 5.2 Colorectal Cancer (CRC) 5.3 CRC and Genetic Instability 5.4 Metabolic Reprogramming in Cancer 5.5 Metabolic Remodeling and Wnt Signaling in Colon Cancer 5.6 Detection/Diagnosis 5.7 Lipid Metabolism 5.8 Tryptophan Metabolism 5.9 Glucose Metabolism 5.10 Exercise Metabolism 5.11 Therapies Based on Pathways 5.12 Metabolic Toxicity in Colon Cancer 5.13 Polyphenols in Colon Cancer 5.14 Gut Metabolism in Colon Cancer 5.15 Metabolic Targets of Colon Cancer 5.16 Future Direction 5.17 Conclusion References Chapter 6: Targeting Metabolic Reprogramming of Colorectal Cancer 6.1 Metabolic Reprogramming 6.2 Colorectal Cancer and Metabolic Changes Associated with Butyrate 6.3 MYC Induced Global Metabolic Reprogramming of Colorectal Cancer 6.4 Targeting Mitochondria and ROS in CRC 6.5 Resveratrol Targeting Pyruvate Dehydrogenase Complex and Reverses the Warburg Effect in Colon Cancer Cells 6.6 MicroRNA-26a Targeting PDHX in Colorectal Cancer Cells 6.7 Reprogramming of Glutamine Metabolism by Oncogenic PIK3CA Mutations in Colorectal Cancer 6.8 Targeting Lipid Metabolism as Therapeutic Strategy in Colorectal Cancer 6.9 Metabolism Based Therapeutic Strategies Targeting CRC Stem Cells 6.10 Targeting Autophagy in Colorectal Cancer 6.11 Conclusion 6.12 Future Direction References Chapter 7: Understanding Colorectal Cancer: The Basics 7.1 Introduction 7.1.1 Epidemiology 7.2 Risk Factors of Colorectal Cancer 7.2.1 Inflammatory Bowel Disease (IBD) 7.2.2 Familial Adenomatous Polyposis (FAP) 7.2.3 Lynch Syndrome 7.2.4 Cholecystectomy 7.2.5 Ureterocolic Anastomosis 7.2.6 Diabetes Mellitus 7.2.7 Pelvic Radiotherapy 7.2.8 Alcohol Consumption 7.2.9 Smoking and Tobacco Consumption 7.2.10 Food Habits 7.2.11 Physical Activity and Obesity 7.2.12 Socioeconomic Status 7.3 Pathways Associated with Pathogenesis of Colorectal Cancer 7.4 Biomarkers of Colorectal Cancer 7.5 Treatment Regimens and Associated Toxicities 7.6 Conclusion References Chapter 8: Molecular Signaling Pathways Involved in Gastric Cancer Chemoresistance 8.1 Introduction 8.2 Oncogenes p53 8.3 Growth Factor Receptor and Signaling 8.4 PI3K/AKT Signaling Pathway Activation 8.5 Mitogen-Activated Protein Kinase Signaling Pathway 8.6 NF-B Signaling Pathways 8.7 EMT 8.8 Conclusion References Chapter 9: Meta-Analysis Reveals no Significant Association of EPHX1 Tyr113His and His139Arg Polymorphisms with the Colorectal... 9.1 Introduction 9.2 Materials and Methods 9.2.1 Data Extraction 9.2.2 Statistical Analysis 9.3 Results 9.3.1 Characteristics of Studies 9.3.2 Meta-Analysis of EPHX1 Tyr113His Polymorphism with CRC Risk 9.3.3 Meta-Analysis Between EPHX1 His139Arg Polymorphism and CRC Risk 9.3.4 Heterogeneity and Sensitivity Analysis 9.3.5 Publication Bias 9.4 Discussion 9.5 Conclusion References Chapter 10: Meta-Analysis of Genetic Variants in Alcohol Metabolizing Enzymes and their Association with Colorectal Cancer Risk 10.1 Introduction 10.2 Materials and Methods 10.2.1 Search Strategy and Selection Criteria 10.2.2 Statistical Analysis 10.3 Results 10.3.1 Characteristics of Included Studies 10.3.2 Heterogeneity Analysis 10.3.3 Overall and Subgroup Analyses for ADH1B Arg47His Polymorphism 10.3.4 Overall and Subgroup Analyses for ALDH2 Glu487Lys Polymorphism 10.3.5 Sensitivity Analysis and Publication Bias 10.4 Discussion References Chapter 11: Gut Microbiota as Signatures in Non-communicable Diseases and Mucosal Immunity 11.1 Gut Microbiota and Human Body 11.2 Role of Gut Microbiota in NCDs 11.3 Gut Microbiota and Metabolic Disorder 11.3.1 Obesity 11.3.2 Type 2 Diabetes (T2D) 11.3.3 Type 1 Diabetes (T1D) Mellitus 11.3.4 Dyslipidemia 11.3.5 Non-alcoholic Fatty Liver Disease (NAFLD) 11.4 Gut Microbiota in Immunological Disorder 11.4.1 Autoimmune Disorder (AD) 11.4.2 Inflammatory Bowel Disease (IBD) 11.4.3 Celiac Disease 11.4.4 Rheumatoid Arthritis (RA) 11.4.5 Systemic Lupus Erythematosus (SLE) 11.5 Role of Gut Microbiota on Neurological Disorders 11.5.1 Autism 11.5.2 Schizophrenia 11.5.3 Alzheimer´s Disease (AD) 11.5.4 Parkinson´s Disease (PD) 11.6 Gut Microbiota in Other Disorders 11.6.1 Cancers 11.6.2 Chronic Heart Diseases 11.6.3 Chronic Kidney Disease (CKD) 11.7 Mucosal Immunity and Gut-Microbiota 11.8 Mucin-Desulfating Sulfatases and Gut Microbiota 11.9 Gut Microbiota and Therapies 11.9.1 Gut Microbiota as Present Drug Targets 11.9.2 Mucosa Associated Gut Bacteria as Future Drug Targets 11.9.3 Pre, Pro, Postbiotics and Feacal Microbiota Transplantation as Therapy References Chapter 12: Immunotherapy for Colon Cancer: Recent Perspectives 12.1 Introduction 12.1.1 Adenocarcinoma 12.1.2 Gastrointestinal Stromal Tumors 12.1.3 Gastrointestinal Carcinoid Tumors 12.1.4 Colorectal Lymphoma 12.1.5 Hereditary Colorectal Cancers 12.2 Symptoms 12.3 Diagnosis 12.3.1 Blood Tests and Imaging 12.3.2 Molecular Testing of the Tumor 12.4 Risk Factors 12.5 Prognosis 12.6 Immunotherapy 12.6.1 Clinical Trials 12.6.2 Total Studies 12.6.3 Clinical Trials Registered in the United States 12.6.4 Immune Checkpoint Inhibitors 12.6.5 Clinical Trials Using PD-1 Inhibitors 12.6.6 Total Studies 12.6.7 Clinical Trials Registered in the United States 12.6.8 Cancer Vaccines 12.7 Vaccine Immunotherapy for CRC Patients 12.7.1 Autologous Vaccines 12.7.2 Total Studies 12.7.3 Clinical Trials Registered in the United States 12.7.4 Adoptive Immunotherapy 12.7.5 Non-specific Immunotherapies 12.7.6 Monoclonal Antibodies (mAbs) 12.8 Recent Developments and Future Perspectives 12.9 Conclusion References Chapter 13: Nanotechnology Applications in Gastric Cancer 13.1 Introduction 13.2 Nanoparticles in Biomedical Imaging for GC Diagnosis and Therapy 13.3 Inorganic Nanoparticles 13.3.1 Gold Nanoparticles 13.3.2 Quantum Dots 13.3.3 Superparamagnetic Iron Oxide Nanoparticles 13.4 Organic Nanoparticles 13.4.1 Dendrimers 13.4.2 Liposomes 13.4.3 Micelles 13.5 Nanoparticles for Drug Delivery 13.6 The Preclinical and Clinical Trials of Nanoparticles 13.7 Conclusion and Future Perspective References